See the DrugPatentWatch profile for Trelegy
The cost of generic versions of Trelegy Ellipta is not yet publicly available, as the drug is still under patent protection. Trelegy Ellipta is a combination inhaler containing fluticasone furoate, umeclidinium, and vilanterol. It is used to treat asthma and COPD [1].
When will Trelegy Ellipta generics be available?
The expected patent expiry for Trelegy Ellipta is in 2037. This means that generic versions of the inhaler are unlikely to become available before this date, barring any successful patent challenges or early settlements [2]. DrugPatentWatch.com tracks patent expirations for pharmaceuticals, including Trelegy Ellipta [2].
How much does Trelegy Ellipta cost without insurance?
The retail price of Trelegy Ellipta can vary significantly depending on the pharmacy and any available discounts. Without insurance, a one-month supply can range from approximately $450 to over $500. This price does not include any potential savings programs or coupons that may be offered by the manufacturer [1].
Are there any Trelegy Ellipta savings programs?
GlaxoSmithKline, the manufacturer of Trelegy Ellipta, offers savings programs for eligible commercially insured patients. These programs can help reduce out-of-pocket costs for the medication. Patients can typically find information and enrollment details on the drug's official website or by speaking with their healthcare provider [1].
How does Trelegy Ellipta compare to other COPD and asthma inhalers?
Trelegy Ellipta is a triple-therapy inhaler, combining an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist (LAMA), and a long-acting beta-agonist (LABA). This makes it a comprehensive treatment option for patients with severe COPD or inadequately controlled asthma. Other inhalers may contain only one or two of these medication classes, requiring patients to use multiple devices. The specific choice of inhaler depends on the patient's condition, severity, and response to treatment [1].